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Background: It has been suggested that coronary artery disease (CAD) is a common compli-
cating condition in pulmonary fibrosis.
Objective: To establish and compare the incidence of coronary artery disease in lung-trans-
plantation candidates with emphysema and lung fibrosis
Method: All adult patients (age> 40 years old) with emphysema or lung fibrosis, candidates for
lung transplantation between January 1997 and December 2003, were included. All patients
underwent pretransplant coronary angiography.
Results: A total of 100 patients were enrolled; 51 with emphysema and 49 with fibrosis. CAD (at
least one 50% stenotic coronary artery) was diagnosed in fourteen of 49 (28.6%) patients with
lung fibrosis as compared to five out of 51 (9.8%) with emphysema, [pZ 0.019] despite the fact
that 98% of patients with emphysema but only 31% of the patients with lung fibrosis were heavy
smokers. The groups didn’t significantly differ in any other cardiovascular risks.
Conclusions: There is significantly more CAD in lung-transplantation candidates with lung
fibrosis as compared to those with emphysema, despite the fact that smoking was much more2 6666278; fax: þ972 2 6666772.
il (G. Izbicki).
9 Elsevier Ltd. All rights reserved.
Coronary disease in lung-transplant candidates 1347prevalent in the emphysema patients. These results suggest that the inflammatory process in
lung fibrosis may involve the coronary arteries as a part of a systemic inflammation rather than
an idiopathic fibrotic disease confined to the lungs.
ª 2009 Elsevier Ltd. All rights reserved.Table 1 Demographic characteristics, cardiovascular risk
factors and coronary artery disease among lung-trans-
plantation candidates, stratified by diagnosis. Results are
expressed as number of patients in each group. NSZ non-
significant (p> 0.05).
Emphysema Fibrosis p-Value
n 51 49
Age (mean SD) years 58.9 5. 6 55.8 6.0 NS
Sex (male/female) 35/16 34/15 NS
Corticosteroid therapy 34 49 <0.0001
Smoking 50 15 <0.0001
Hypertension 10 7 NS
Diabetes mellitus 11 10 NS
Hypercholesterolemia 19 11 NS
Obesity 9 16 NS
Coronary artery disease 5 14 0.019Introduction
Lung transplantation is now accepted therapy for diseases
that cause end-stage pulmonary disability,1 principally
emphysema and pulmonary fibrosis.2 Coronary artery
disease (CAD) was previously considered an absolute
contraindication for lung transplantation, based on the
shortage of organs for transplantation, the need to select
the best possible candidates, and the potential negative
impact of CAD on the morbidity and mortality during and
after lung transplantation. However, improvements in
management of CAD have removed it from the list of
contraindications for lung transplantation.3 Nonetheless,
CAD remains an important potential complicating factor for
patients being considered for transplantation.
Recently, Kizer et al. showed an association between
CAD and pulmonary fibrosis.4 Among 186 patients being
considered for lung transplantation, the prevalence of CAD
(15.9%) was significantly higher than its prevalence among
the 444 non-fibrotic patients (10.6%), most but not all of
whom had COPD. We undertook this study to confirm Kizer’s
findings in a different population of patients and to make
a direct comparison between lung-transplantation candi-
dates with emphysema and those with pulmonary fibrosis.
Patients and methods
All adult patients with emphysema or pulmonary fibrosis,
candidates for lung transplantation in our institution
between January 1997 and December 2003, were included
in this study. Emphysema was diagnosed by pulmonary
function tests and chest-X-ray radiography or chest CT-
scan, according to the ATS/ERS position paper.5 The diag-
nosis of pulmonary fibrosis was established according to the
ATS statement on idiopathic interstitial pneumonias.6
Each patient was evaluated for the presence of following
cardiovascular risk factors: hypertension, hypercholester-
olemia, diabetes mellitus, obesity, and smoking status. In
addition, treatment with glucocorticosteroids during the
study was recorded. Hypertension was defined as arterial
blood pressure 140/90 mmHg or treatment with one or
more antihypertensive agents. Hypercholesterolemia was
defined as total blood cholesterol level of 240 mg/dl or
treatment with one or more lipid-lowering drug. Diabetes
mellitus was defined as a fasting serum glucose level
126 mg/dl or treatment with one or more oral or paren-
teral hypoglycemic medications. Obesity was defined as
a body mass index, BMI 27.0.
Significant CAD was defined by 50% stenosis of one or
more coronary arteries, as reported in the coronary angi-
ography report reviewed for each patient. Non-clinically
significant CAD was defined 20% to <50% stenosis.
Absence of CAD was defined as either the absence of
stenosis or a stenosis of <20%.Statistics
In order to compare the different parameters between both
groups the two-sided Fisher’s exact test was used. p< 0.05
was considered significant.
Hierarchical logistic regression was conducted in order
to test the relationship between the diagnosis and CAD
while controlling possible confounding factors.
Results
A total of 100 patients were enrolled in this study; 51 with
emphysema and 49 with pulmonary fibrosis. Demographic
characteristics are shown in Table 1. There was no signifi-
cant difference in the age and gender between both
groups.
Almost all patients with emphysema (98%) were
smokers, in comparison to only 30.6% in the fibrosis group
(p< 0.0001) (Table 1). All patients in the fibrosis group
(100%) had been treated with corticosteroids, but only
66.6% in the emphysema group (p< 0.0001). There was
a trend toward higher prevalence of hypercholesterolemia
among patients with emphysema (37.2%) as compared to
fibrotic patients (22.4%, pZ 0.129), but without reaching
statistical significance. There was no significant difference
in the other cardiovascular risk factors.
Multivariate analysis was done in order to test for
possible confounding factors. Fourteen of 49 patients
(28.6%) with pulmonary fibrosis as compared to five out of
51 (9.8%) with emphysema had significant CAD
(c2(1)Z 4.57, pZ 0.019) (Fig. 1) when hierarchical logistic
regression was done. Only the differences in single-vessel
disease reached statistical significance. Two of the
emphysema patients and 4 of the fibrotic patients had been
Figure 1 Prevalence of CAD among emphysema and pulmo-
nary fibrosis patients referred for evaluation for lung trans-
plantation. Significant CAD (at least one vessel with at least
50% stenosis) was threefold greater among fibrosis than
emphysema patients despite the higher prevalence of smoking
among the emphysema patients (98% vs. 31% for fibrosis). The
absence of CAD (<20% stenosis) was significantly lower in
fibrosis patients as compared to emphysema patients.
1348 G. Izbicki et al.revascularized, a difference that did not reach statistical
significance. No significant difference was found in any
other cardiovascular risk between the fibrotic and emphy-
sema groups.
Discussion
We have shown that coronary artery disease is significantly
more prevalent in lung-transplantation candidates with
lung fibrosis (28.6%) as compared to those with emphysema
(9.8%), despite the fact that far more of the emphysema
patients had been cigarette smokers. Moreover, there was
no statistically significant difference in the other cardio-
vascular risk factors between both groups.
The association between pulmonary fibrosis and CAD
may be explained by the similarities in their pathogenesis.
Fibroblastic proliferation and excessive collagen deposi-
tion, whether of lung or coronary arteries, occur either as
a direct result of the injury, as a result of anti-inflammatory
cell response that releases pro-inflammatory and pro-
fibrotic cytokines, or as a consequence of the regenerative
and reparative processes taking place at the epithelial and
endothelial surfaces.7,8 Laboratory and pathological data
support the idea that inflammation has a role on both the
initiation and the progression of atherosclerosis. It has been
shown that high level of pro-inflammatory mediators such
as interleukin-6, and high-reactivity C-reactive protein
were present in patients with coronary artery disease9 and
their presence was predictive of cardiovascular events in
patients with stable10 and unstable angina,11 as well as in
healthy men12 and women.13 The active inflammatory
process plays a major role in plaque destabilization leading
to acute coronary syndrome. Furthermore, some evidence
suggests that anti-inflammatory agents may have a role in
the prevention of cardiovascular disease.14 Several lines of
evidence also suggest that the fibroproliferative lung
process can have systemic effects. Levels of cytokines and
growth factors as well as biologically active eicosanoidshave been found to be elevated in the sera or urine of
patients with lung fibrosis. Hence, the fibroproliferative
process seems to affect cells beyond the pulmonary
compartment, and the many mediator molecules produced
in these disorders provide multiple potential mechanisms
through which they might promote atherogenesis.4
Although the pathogenesis of interstitial pulmonary
fibrosis has not been fully elucidated, actual concepts
focused on lung injury leading to a cycle of chronic alveolar
inflammation leading to exaggerated fibroblast prolifera-
tion, and excessive deposition of collagen eventuating in
fibrosis and destruction of the lung architecture.15 Inte-
leukin-1 beta and TNF-alpha especially have been shown to
increased lung TGF-beta levels, proportionate to the
degree of fibrosis generated.16 Anti-inflammatory therapies
employing corticosteroids or immunosuppressive agents
alone or as combination therapy have been disappointing.17
Our results may suggest that the inflammatory process in
pulmonary fibrosis could eventually involve the coronary
arteries as a part of a systemic inflammatory disease,
rather than an idiopathic disease confined to the lungs.
Similarly, it was recently shown that coronary artery
atherosclerosis detected by electron-beam CT, is more
common in patients with lupus that in the general pop-
ulation but is not associated with traditional coronary risk
factors, lupus disease activity, or corticosteroid therapy.18
In conclusion, our findings suggest that coronary artery
disease is more prevalent among lung-transplantation
candidates with pulmonary fibrosis as compared to those
with emphysema, despite the fact that emphysema patients
have a much greater exposure to cigarette smoking. This
tendency to develop significant coronary artery disease
among patients with fibrosis as compared to emphysema
cannot be predicted by the measurement of traditional risk
factors. These results may suggest that the inflammatory
process in lung fibrosis could be a systemic disease rather
than an idiopathic fibrosis confined to the lungs.Conflict of interest
The authors have no conflict of interest.
References
1. International guidelines for the selection of lung transplant
candidates. The American Society for Transplant Physicians
(ASTP)/American Thoracic Society (ATS)/European Respiratory
Society (ERS)/International Society for Heart and Lung
Transplantation (ISHLT). Am J Respir Crit Care Med 1998;158:
335e9.
2. Trulock EP, Edwards LB, Taylor DO, et al. The registry of the
international society for heart and lung transplantation.
J Heart Lung Transplant 2004;23:804e15.
3. Lee R, Meyers BF, Sundt T, et al. Concomitant coronary artery
revascularization to allow successful lung transplantation in
selected patients with coronary artery disease. J Thorac Car-
diovasc Surg 2002;124:1250e1.
4. Kizer JR, Zisman DA, Blumenthal NP, et al. Association between
pulmonary fibrosis and coronary artery disease. Arch Intern
Med 2004;164:551e6.
5. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the
diagnosis and treatment of patients with COPD: a summary
Coronary disease in lung-transplant candidates 1349of the ATS/ERS position paper. Eur Respir J 2004;23:
932e46.
6. ATS/ERS International multidisciplinary consensus classifica-
tion of the idiopathic interstitial pneumonias. Am J Respir Crit
Care Med 2002;165:277e304.
7. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med
1999;340:115e26.
8. Strieter RM, Keane MP, Standtford TK, Kunkel SL. Cytokine
biology and the pathogenesis of interstitial lung disease. In:
Schwartz MI, King TE, editors. Interstitial lung diseases. 3rd
ed. Hamilton, Ontario: BC Decker Inc.; 1998. p. 181e205.
9. Rifai N, Joubran R, Yu H, et al. Inflammatory markers in men
with angiographically documented coronary heart disease. Clin
Chem 1999;45:1967e73.
10. Ikonomidis I, Andreotti F, Economou E, et al. Increased
proinflammatory cytokines in patients with chronic stable
angina and their reduction by aspirin. Circulation 1999;100:
793e8.
11. Biasucci L, Vitelli A, Liuzzo G, et al. Elevated levels of inter-
leukin-6 in unstable angina. Circulation 1996;94:874e7.12. Ridker P, Cushman M, Stampfer M, et al. Inflammation, aspirin,
and the risk of cardiovascular disease in apparently healthy
men. N Engl J Med 1997;336:973e9.
13. Ridker P, Hennekens C, Buring J, et al. C-reactive protein and
other markers of inflammation in the prediction of cardiovas-
cular disease in women. N Engl J Med 2000;342:836e43.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for
the 1990s. Nature 1993;362:801e9.
15. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ,
Lynch 3rd JP. Idiopathic pulmonary fibrosis: pathogenesis and
therapeutic approaches. Drugs 2004;64:405e30.
16. Kelly M, Kolb M, Bonniaud P, Gauldie J. Re-evaluation of fibro-
genic cytokines in lung fibrosis. Curr Pharm Des 2003;9:39e49.
17. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-
Everett D, King Jr TE, et al. Combined corticosteroid and
cyclophosphamide therapy does not alter survival in idiopathic
pulmonary fibrosis. Chest 2004;125:2169e74.
18. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S,
et al. Premature coronary-artery atherosclerosis in systemic
lupus erythematosus. N Engl J Med 2003;349:2407e15.
